Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19(m1) in exon 5 and CYP2C19(m2) in exon 4, in Japanese subjects

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 6, 1996, Pages 647-653

  Ieiri, Ichiro ^a   Kubota, Takahiro ^b   Urae, Akinori ^b   Kimura, Miyuki ^b   Wada, Yukiko ^b   Mamiya, Kosuke ^b   Yoshioka, Shinichi ^b   Irie, Shin ^b   Amamoto, Toshiaki ^b   Nakamura, Koichi ^b   Nakano, Shigeyuki ^b   Higuchi, Shun ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; OMEPRAZOLE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; MUTATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; VOLUNTEER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; EXONS; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; JAPAN; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MUTATION; OMEPRAZOLE;

EID: 12644315063     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90004-1     Document Type: Article

References (23)

1. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992:657-85.
2. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL. Evidence that CYP2C19 is the major S-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
3. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther 1993;53:608-10.
4. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991;49:18-23.
5. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989;45:72-9.
6. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between orientals and caucasians. Br J Clin Pharmacol 1985;19:483-7.
7. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic differences in genetic polymorphism between Japanese and Caucasian population. Clin Pharmacol Ther 1985;38:402-8.
8. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
9. - on gastric acid secretion. Am J Physiol 1983;245:G64-71.
10. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2: 32-7.
11. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolisers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12:415-6.
12. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992;262:1195-202.
13. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in human. J Biol Chem 1994;269:15419-22.
14. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
15. Kobayashi K, Chiba K, Sohn DR, Kato Y, Ishizaki T. Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column. J Chromatogr 1992;579:299-305.
16. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-8.
17. Andersson T, Andren K, Cederberg C, Lagerstrom PO, Lundborg P, Skanberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990;29:557-63.
18. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991;20:38-49.
19. Maton PN. Omeprazole. N Engl J Med 1991;324:965-75.
20. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 1993;266:52-9.
21. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993;36:521-31.
22. Brockmoller J, Rost KL, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron 4/exon 5 G→A-splice site mutation. Pharmacogenetics 1995;5:80-8.
23. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994;16:214-5.